Sargramostim (GM-CSF) + PD-1

Summary

This research study is testing the combination of two drugs, sargramostim and pembrolizumab. The study is designed to see if the combination of these study drugs would improve the control of unresectable or metastatic melanoma cancer when compared to use of these drugs alone. The names of the study drugs involved in this study are: * Pembrolizumab * Sargramostim (GM-CSF)

Timeline

Start

2021-04-16

Primary completion

2024-06-10

Completion

2025-06-09

Outcome

Outcome not reported

Stopped: “Study terminated by sponsor”

Drugs

Indications